359 related articles for article (PubMed ID: 29079654)
1. Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.
Lee H; Hodi FS; Giobbie-Hurder A; Ott PA; Buchbinder EI; Haq R; Tolaney S; Barroso-Sousa R; Zhang K; Donahue H; Davis M; Gargano ME; Kelley KM; Carroll RS; Kaiser UB; Min L
Cancer Immunol Res; 2017 Dec; 5(12):1133-1140. PubMed ID: 29079654
[TBL] [Abstract][Full Text] [Related]
2. Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma.
Ariyasu H; Inaba H; Ota T; Yamaoka H; Furukawa Y; Iwakura H; Doi N; Yamamoto Y; Akamizu T
In Vivo; 2018; 32(2):345-351. PubMed ID: 29475919
[TBL] [Abstract][Full Text] [Related]
3. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
4. The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders.
Ma C; Hodi FS; Giobbie-Hurder A; Wang X; Zhou J; Zhang A; Zhou Y; Mao F; Angell TE; Andrews CP; Hu J; Barroso-Sousa R; Kaiser UB; Tolaney SM; Min L
Cancer Immunol Res; 2019 Jul; 7(7):1214-1220. PubMed ID: 31088848
[TBL] [Abstract][Full Text] [Related]
5. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
[TBL] [Abstract][Full Text] [Related]
6. [Thyroid dysfunctions secondary to cancer immunotherapy].
Cugnet Anceau C; Abeillon J; Maillet D; Borson-Chazot F; Disse E
Bull Cancer; 2020 Feb; 107(2):262-271. PubMed ID: 31879018
[TBL] [Abstract][Full Text] [Related]
7. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
Iyer PC; Cabanillas ME; Waguespack SG; Hu MI; Thosani S; Lavis VR; Busaidy NL; Subudhi SK; Diab A; Dadu R
Thyroid; 2018 Oct; 28(10):1243-1251. PubMed ID: 30132401
[TBL] [Abstract][Full Text] [Related]
8. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
Wu X; Giobbie-Hurder A; Liao X; Connelly C; Connolly EM; Li J; Manos MP; Lawrence D; McDermott D; Severgnini M; Zhou J; Gjini E; Lako A; Lipschitz M; Pak CJ; Abdelrahman S; Rodig S; Hodi FS
Cancer Immunol Res; 2017 Jan; 5(1):17-28. PubMed ID: 28003187
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders.
Jannin A; Penel N; Ladsous M; Vantyghem MC; Do Cao C
Crit Rev Oncol Hematol; 2019 Sep; 141():23-35. PubMed ID: 31202955
[TBL] [Abstract][Full Text] [Related]
10. Delayed-onset immune-related adverse events involving the thyroid gland by immune checkpoint inhibitors in combination with chemotherapy: a case report and retrospective cohort study.
Ueba Y; Yamauchi I; Hakata T; Fujita H; Okamoto K; Ikeda K; Ueda Y; Fujii T; Taura D; Inagaki N
Endocr J; 2023 Mar; 70(3):323-332. PubMed ID: 36464271
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index.
Pollack R; Ashash A; Cahn A; Rottenberg Y; Stern H; Dresner-Pollak R
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32668461
[TBL] [Abstract][Full Text] [Related]
12. [Clinical characteristics and risk factors of programmed death-1 inhibitors associated with thyroid gland injury].
Gong WW; Zhou FY; Guo QH
Zhonghua Nei Ke Za Zhi; 2023 Feb; 62(2):176-181. PubMed ID: 36740408
[No Abstract] [Full Text] [Related]
13. Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients.
Campredon P; Mouly C; Lusque A; Bigay-Game L; Bousquet E; Mazières J; Caron P
Presse Med; 2019 Apr; 48(4):e199-e207. PubMed ID: 31005502
[TBL] [Abstract][Full Text] [Related]
14. Common thyroid disorders.
Sakiyama R
Am Fam Physician; 1988 Jul; 38(1):227-38. PubMed ID: 3293385
[No Abstract] [Full Text] [Related]
15. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities.
Cousin S; Italiano A
Clin Cancer Res; 2016 Sep; 22(18):4550-5. PubMed ID: 27435397
[TBL] [Abstract][Full Text] [Related]
16. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
Wu L; Xu Y; Wang X; Cheng X; Zhang Y; Wang Y; Fan X; Zhao H; Liu H; Chai X; Zhang L; Wang M; Li N; Pan H; Lian X
Endocrine; 2023 Jul; 81(1):123-133. PubMed ID: 36867366
[TBL] [Abstract][Full Text] [Related]
17. On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
Colombo MP
Clin Cancer Res; 2017 Oct; 23(20):5999-6001. PubMed ID: 29030331
[TBL] [Abstract][Full Text] [Related]
18. Expert opinion on thyroid complications in immunotherapy.
Illouz F; Drui D; Caron P; Do Cao C
Ann Endocrinol (Paris); 2018 Oct; 79(5):555-561. PubMed ID: 30126627
[TBL] [Abstract][Full Text] [Related]
19. Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma.
Lu Y; Li Q; Xu L; Zheng Y; Wang Y; Liu Y; Zhang R; Liao L; Dong J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16501-16510. PubMed ID: 37715029
[TBL] [Abstract][Full Text] [Related]
20. Thyroid diseases after treatment of Hodgkin's disease.
Hancock SL; Cox RS; McDougall IR
N Engl J Med; 1991 Aug; 325(9):599-605. PubMed ID: 1861693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]